Lennox-Gastaut syndrome

7 trials MedDRA PT
7 Registered trials
0 Recruiting
5 Unique sponsors
5 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Phase III: 6 Phase II: 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

6 trials
  • Epygenix Therapeutics Inc. Commercial
    CLEMIZOLE HYDROCHLORIDE
    2025-522552-20-00 6 countries n=98
    Pending
  • Gw Research Limited Commercial
    CANNABIDIOL
    2023-505851-33-00 2 countries 2024 n=10 Orphan
    Ended
  • Sk Life Science Inc. Commercial
    CARISBAMATE
    2023-506616-41-00 7 countries 2023 n=92
    Ended
  • Takeda Development Center Americas Inc. Commercial
    SOTICLESTAT
    2022-502802-34-00 10 countries 2022 n=127 Orphan
    Ended
  • Takeda Development Center Americas Inc. Commercial
    SOTICLESTAT
    2023-504104-29-00 1 country 2024 n=5 Orphan
    Ended
  • Zogenix International Limited Commercial
    FENFLURAMINE HYDROCHLORIDE
    2024-515680-61-00 4 countries 2020 n=104 Orphan
    Ended

Phase II

1 trial
  • Takeda Development Center Americas Inc. Commercial
    SOTICLESTAT
    2022-502801-13-00 3 countries 2019 n=51 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Takeda Development Center Americas Inc. Commercial 3 Phase II, Phase III 0
Epygenix Therapeutics Inc. Commercial 1 Phase III 0
Gw Research Limited Commercial 1 Phase III 0
Sk Life Science Inc. Commercial 1 Phase III 0
Zogenix International Limited Commercial 1 Phase III 0
New trials by year
2019
1
2020
1
2022
1
2023
1
2024
2
← All indication landscapes